Tavapadon is a potent, orally-bioavailable, selective partial agonist of the dopamine D1 and D5 receptors.

GNE-7915 is a highly potent, selective, and brain-penetrable LRRK2 small molecule inhibitor with IC50 of 9 nM in cellular LRRK2 assay; > 100 fold selectivity against a panel of 187 kianses(Ki).

Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor.

JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor.

BP897 is a partially selective D3 dopamine receptor agonist.

Tozadenant (SYN-115) is an adenosine A2A receptor antagonist.

Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.

Rotigotine is dopamine D2 and D3 receptor agonist. Ki values are 13 and 0.71 nM for D2 and D3 respectively. Rotigotine also has significant affinity for 5-HT1A and adrenergic α2B receptors. Rotigotine exhibits antiparkinsonian acitivity.

Pramipexole is a partial/full D2S, D2L, D3, D4, receptor agonist with a Ki of 3.9, 2.2, 0.5, 5.1 nM.

Pramipexole is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).

For the detailed information of GPI-1046, the solubility of GPI-1046 in water, the solubility of GPI-1046 in DMSO, the solubility of GPI-1046 in PBS buffer, the animal experiment (test) of GPI-1046, the cell expriment (test) of GPI-1046, the in vivo, in vitro and clinical trial test of GPI-1046, the EC50, IC50,and Affinity of GPI-1046, Please contact DC Chemicals..

A potent, selective, brain-penetrant and orally bioavailable mGluR4 positive allosteric modulator with EC50 of 79 nM.

A potent, selective, brain-penetrant and orally bioavailable mGluR4 positive allosteric modulator with EC50 of 79 nM.

A novel 5-HT receptor antagonist for the treatment of Parkinson's disease..